GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (STU:K6S) » Definitions » Treasury Stock

Mira Pharmaceuticals (STU:K6S) Treasury Stock : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Mira Pharmaceuticals Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Mira Pharmaceuticals's treasury stock for the quarter that ended in Sep. 2024 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Mira Pharmaceuticals Treasury Stock Historical Data

The historical data trend for Mira Pharmaceuticals's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Treasury Stock Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Treasury Stock
- - -

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mira Pharmaceuticals Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Mira Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Mira Pharmaceuticals Headlines

No Headlines